PT  - JOURNAL ARTICLE
AU  - Esai Selvan, Myvizhi
AU  - Kuan, Pei-Fen
AU  - Yang, Xiaohua
AU  - Mascarenhas, John
AU  - Klein, Robert J.
AU  - Luft, Benjamin J.
AU  - Boffetta, Paolo
AU  - Gümüş, Zeynep H.
TI  - Distinct characteristics of lymphoid and myeloid clonal hematopoiesis in Word Trade Center first responders
AID  - 10.1101/2024.08.01.24311359
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.08.01.24311359
4099  - http://medrxiv.org/content/early/2024/08/02/2024.08.01.24311359.short
4100  - http://medrxiv.org/content/early/2024/08/02/2024.08.01.24311359.full
AB  - BACKGROUND Clonal hematopoiesis of indeterminate potential (CHIP) is a condition when healthy individuals harbor clonal mutations in myeloid (M-CHIP) and/or lymphoid (L-CHIP) cells at variant allele fraction (VAF) ≥0.02. While CHIP is associated with an increased risk of hematologic malignancy and cardiovascular disease, its association with airborne carcinogens is largely unknown.OBJECTIVES Here, we studied M/L-CHIP in responders to the 9/11 terrorist attacks on the World Trade Center (WTC), who were exposed to a complex mix of airborne carcinogens. Then we explored the association of CHIP mutations with phenotypes such as age, ancestry, exposure, HLA zygosity, and other clinical, laboratory, mental and cognitive data. Finally, we compared CHIP prevalence in WTC responders to 293 unexposed controls.METHODS Using banked peripheral blood and ultra-deep whole-exome sequencing at 250X, we characterized CHIP mutations and their interaction with clinical, mental and cognitive characteristics, exposure, peripheral blood counts, and HLA zygosity in 350 WTC responders. We used Fisher’s exact test for categorical variables; Wilcoxon rank sum test for continuous variables; and logistic regression for multivariate analysis.RESULTS Among WTC participants, M-CHIP prevalence was 16.2% and L-CHIP 21.4%. M-CHIP prevalence increased with age (p=0.02), was elevated in previous-smokers (p=0.01), and associated with lower platelet counts (p=0.03). The most frequently occurring genes for M-CHIP were DNMT3A, TET2, PPM1D and for L-CHIP were EEF1A1, DDX11 and KMT2D. Notably, harboring a DDX11 mutation associated with a lower Montreal Cognitive Assessment score (p=6.57e-03). Overall, M/L-CHIP was more prevalent in WTC responders versus controls.DISCUSSION Study results will inform the development of personalized risk-adapted CHIP and cancer screening programs in individuals exposed to airborne carcinogens.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants to P.B., J.M. and Z.H.G. from the Centers for Disease Control and Prevention, National Institute of Occupational; Safety and Health (award # 1U01OH012187-01); to Z.H.G from Cancer Moonshot R33 award # CA263705-01; to B.J.L. and X.Y. from the Centers for Disease Control and Prevention (CDC/NIOSH 75D301-22-C-15522); and in part through the computational and data resources and staff expertise provided by Scientific Computing and Data at the Icahn School of Medicine at Mount Sinai and supported by the Clinical and Translational Science Awards (CTSA) grant UL1TR004419 from the National Center for Advancing Translational Sciences.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved under IRB #604113 by the Committees on Research Involving Human Subjects at Stony Brook UniversityI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesWe will deposit the whole exome sequencing data of the WTC responders in the database of Genotypes and Phenotypes (dbGaP).